Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response	: 0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transaction Code (Instr.	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial			
		Table I - No	n-Derivative S	ecurities Acq	uired, Disp	oosed of, or Benef	icially	Owned				
(City)	(State)	(Zip)										
	1011 1	02110						Form filed by Mo Person	re than One Re	porting		
(Street) BOSTON	MA	02110					X	Form filed by On	e Reporting Per	son		
			4. If A	mendment, Date of	Original Filed	(Month/Day/Year)	6. Indiv Line)	/idual or Joint/Grou	p Filing (Check	Applicable		
125 SUMME	R STREET											
(Last)	(First)	(Middle)		te of Earliest Transa	action (Month/	Day/Year)		Officer (give title below)	Other below	(specify)		
<u>Zane Ellen M</u>				EMONETICS	<u>S CORP</u> [HAE		Director	10% 0	Dwner		
1. Name and Address of Reporting Person*				uer Name and Ticke	0	·	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
1 Name and Ad	dross of Boporting	Porcon*	2. Issu	uer Name and Ticke	er or Trading S	Symbol	5. Relationship of Reporting Person(s) to Issu					

	(Month/Day/Year)	(Month/Day/Year)	8)					Owned Following Reported	(I) (Instr. 4)	Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	08/06/2021		A		3,0 77 ⁽¹⁾	A	(2)	9,517	D	
						_	с · н	. .		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv	r osed) r. 3, 4	Expiration Date (Month/Day/Year) es d		Expiration Date Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

<u>/s/ Thomas V. Powers,</u> <u>attorney-in-fact for Ms. Zane</u>

08/09/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.